Cell Viability Assay Market Size, Share | Report 2022-2030
The global cell viability assay market size was estimated at around USD 3.53 billion in 2021 and it is projected to hit around USD 7.40 billion by 2030, growing at a CAGR of 8.57% from 2022 to 2030.
Cell viability is defined as the presence of viable or living cells and is considered as an indicator of good cell health. In many studies, it is the viability levels that are altered due to an event of physical or chemical agents, such as in toxicity assays. Cell viability assays (CVAs) are used to determine the cellular response to any drug or pathogenic agent and thus has found wide application in medical and pharmaceutical industries.
The rise in incidence of infectious diseases and genomic disorders has driven research activities towards cell-based research. Cellular-based research allows easy target identification and coupled with the advances in synthetic & molecular biology techniques, it has generated a huge understanding of many disease mechanisms. The understanding of cellular metabolism along with pathogenesis has boosted drug discovery programs for the betterment of health infrastructure. During these drug discovery programs, CVAs are used to evaluate the influence of developing therapeutics on targeted cells and are also often helpful in drug screening stages. For instance, in August 2020 Calidi Biotherapeutics Inc. announced that its partner, Personalized Stem Cells, Inc. has received the US FDA approval for the IND (investigational new drug) application submitted. The submitted IND was for the treatment of patients suffering from COVID-19 and pneumonia by using stem-cell therapy. Therefore, the increase in cellular-based therapies will essentially increase the use of CVAs for understanding the response of live cells and viability for any line of treatment.
Several types of assays are used to determine the viable cells or viability. These CVAs are based on various functions including enzymatic activity, ability to permeate cellular membrane, ATP (adenosine triphosphate) production, cellular adherence, enzyme production, nucleotide uptake, and metabolic activity. Different detection methods like flow cytometry, luminometric method, fluorescent mediated detection & spectrophotometry, colorimetric method, and microscopy among many others are employed for CVAs.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 3.53 billion |
| Revenue Forecast by 2030 | USD 7.40 billion |
| Growth rate from 2022 to 2030 | CAGR of 8.57% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product, Application, End-user, Region |
| Companies Covered |
Sartorius AG, Abcam plc., Promega Corporation, Merck KGaA, Danaher Corporation, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc. |
Cell viability assay market has wide applications, a few of these are;
The drug development & discovery program involves therapeutics target discovery and screening on live cells to identify the treatment regimen. Cell viability assays provide the same understanding in a rapid, accurate, and potentially in automated manner. These assays also help understand the cell proliferation and cytotoxicity in in-vitro models and are thus helpful in research activities such as stem cell, cancer, and others including neurology, immunology & basic research. Actively living & dividing cells have increased metabolic activities whereas those exposed to toxic agents have decreased cellular activity. This metabolism feature is involved in assays such as MTT, XTT, and WST-1 wherein, measuring the metabolic activity, and helps analyze the proliferation, cytotoxicity, and viability.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell Viability Assay Market
5.1. COVID-19 Landscape: Cell Viability Assay Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell Viability Assay Market, By Product
8.1. Cell Viability Assay Market, by Product, 2022-2030
8.1.1 Instrument
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cell Viability Assay Market, By Application
9.1. Cell Viability Assay Market, by Application, 2022-2030
9.1.1. Drug development & discovery
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Stem cell research
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Clinical & diagnostics
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Cancer research
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cell Viability Assay Market, By End-user
10.1. Cell Viability Assay Market, by End-user, 2022-2030
10.1.1. Hospitals & Diagnostic Laboratories
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Academic & Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Pharmaceutical & Biotechnological Companies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cell Viability Assay Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Sartorius AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abcam plc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Promega Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck KGaA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Danaher Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Thermo Fisher Scientific Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bio-Rad Laboratories, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers